PFE240719C23000
- 4.40
- 0.000.00%
Pfizer Newsroom
Valneava and Pfizer Nearing Lyme Vaccine Milestone
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.RBC Capital Markets anticipates a favorable second-quarter
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
On Wednesday, Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme
Express News | President Biden's Doctor Says President Biden's Vital Signs Remain Normal; He Will Continue To Conduct U.S. Business; Continues To Receive Paxlovid; Still Experiencing Mild Covid-19 Symptoms
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc (NYSE:PFE), one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.
Pfizer Options Spot-On: On July 17th, 236.13K Contracts Were Traded, With 2.92 Million Open Interest
On July 17th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 236.13K options for the day, of which put options accounted for 21.65% of the total transactions, and
Express News | OPKO Health Inc: Also Permits OPKO to Maintain Full Benefit of $100 Mln of Remaining Potential Milestone Payments From Pfizer
Express News | OPKO Health Enters Into $250M Non-Dilutive Note Purchase Agreement With HealthCare Royalty Secured By Profit Share Payments From Pfizer For NGENLA
Pfizer And Valneva Announce Primary Vaccination Series Completion In Phase 3 VALOR Lyme Disease Trial; Participants Completed Primary Vaccination Series (3 Doses) With VLA15
Participants completed primary vaccination series (3 doses) with VLA15Primary vaccination series to be followed by a booster approximately one year after completionNew York, NY and Saint-Herblain (
Express News | Valneva SE: Pfizer Plans to Submit a Biologics License Application (Bla) to FDA & Emai N 2026.
Express News | Valneva - Primary Vaccination Series to Be Followed by a Booster Approximately One Year After Completion
Pfizer's Mixed Outlook: Hold Rating Amidst Vyndaqel's Growth and Falling Demand for Comirnaty and Paxlovid
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
Nvidia continues to enter the health care AI industry and collaborates with Pfizer and other investors in CytoReason, a research and development company for AI therapy models.
The current private placement financing raised a total of 80 million US dollars. The company stated that it plans to use this financing to expand the application of its model to more indications and increase its proprietary molecular and clinical data. In addition, the company has strengthened its platform with Nvidia's latest accelerated computing and AI platforms, achieving acceleration of inference workloads exceeding 10 times.
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE:PFE) moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during the second half of the year.
Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk
By Eleanor Laise Selloff of weight-loss drug developers' stocks is overdone, some analysts say Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure
Nvidia, Pfizer Lead $80 Million Funding for Israeli Medical AI Tech Firm CytoReason
CytoReason Secures $80M From OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
New funding will expand CytoReason's disease models and proprietary data, enabling R&D leaders at partner companies to make strategic decisions with greater speed and precision.TEL AVIV, Israel--(
Pfizer Options Spot-On: On July 16th, 125.33K Contracts Were Traded, With 2.91 Million Open Interest
On July 16th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 125.33K options for the day, of which put options accounted for 23.31% of the total transactions, and